High Immunohistochemical Expression of TGF-β1 Predicts a Poor Prognosis in Cervical Cancer Patients who Harbor Enriched Endoglin Microvessel Density

Abstract Previously, we found that sperm-associated antigen 5 (SPAG5) was upregulated in pelvic lymph node metastasis–positive cervical cancer. The aim of this study is to examine the role of SPAG5 in the proliferation and tumorigenicity of cervical cancer and its clinical significance in tumor progression. In our study, SPAG5 expression in cervical cancer patients was detected using quantitative real-time polymerase chain reaction, western blotting, and immunohistochemistry; cervical cancer cell function with downregulated SPAG5 in vitro was explored using tetrazolium assay, flow cytometry, and colony formation and Transwell assays. SPAG5 was upregulated in tumor tissue compared with paired adjacent noncancerous tissues; SPAG5 upregulation in tumor tissues indicated poor disease-free survival, which was also an independent prognostic indicator for cervical cancer patients. In vitro study demonstrated that SPAG5 downregulation inhibited cell proliferation and growth significantly by G2/M arrest and induction of apoptosis, and hindered cell migration and invasion. Under SPAG5 downregulation, the sensitivity of cervical cancer cells differed according to taxol dose, which correlated with mammalian target of rapamycin (mTOR) signaling pathway activity. In general, SPAG5 upregulation relates to poor prognosis in cervical cancer patients, and SPAG5 is a regulator of mTOR activity during taxol treatment in cervical cancer.

Download Full-text

Cytochrome 4Z1 Expression Is Correlated with Poor Prognosis in Patients with Cervical Cancer

Current Oncology ◽

10.3390/curroncol28050306 ◽

2021 ◽

Vol 28 (5) ◽

pp. 3573-3584

Author(s):

Yousef M. Al-saraireh ◽

Fatemah O. F. O. Alshammari ◽

Ahmed M. M. Youssef ◽

Yahya M. Al-sarayra ◽

Renata A. Al-saraireh ◽

...

Keyword(s):

Cervical Cancer ◽

Lymph Node ◽

Cancer Patients ◽

Poor Prognosis ◽

Patient Survival ◽

Tumour Stage ◽

Tumour Invasion ◽

Cervical Cancers ◽

Node Metastasis ◽

Normal Cervix

Background: cervical cancer is one of the most common malignancies in women worldwide and its management remains challenging and complex. As Cytochrome4Z1 (CYP4Z1) is overexpressed in many tumours, its expression in cervical cancer is unknown. Therefore, the present study aimed to evaluate CYP4Z1 expression in cervical cancers. Methods: CYP4Z1 expression was immunohistochemically assessed in 100 cases of cervical cancers along with ten normal cervix tissues, and the enzyme’s relationship to several clinicopathological features and survival was explored. Results: CYP4Z1 was strongly expressed in 55% of cervical cancer patients. Normal cervix samples were negative for CYP4Z1 expression. Importantly, this expression was significantly found in patients with the late stage of the disease, lymph node metastasis, and high tumour invasion (p < 0.05). Interestingly, CYP4Z1 expression was significantly correlated with shorter survival times of cervical cancer patients. Univariate analysis showed that CYP4Z1 expression, tumour stage, lymph node metastasis, and tumour invasion were significantly correlated with patient survival (p < 0.05). The multivariate analysis revealed that only CYP4Z1 expression and tumour stage were significantly correlated with patient survival (p < 0.05). Conclusions: CYP4Z1 expression is associated with cervical cancer patients’ survival and may serve as an independent predictor of poor prognosis in cervical cancer patients.

Download Full-text

Increased ATG5 Expression Predicts Poor Prognosis and Promotes EMT in Cervical Carcinoma

Frontiers in Cell and Developmental Biology ◽

10.3389/fcell.2021.757184 ◽

2021 ◽

Vol 9 ◽

Author(s):

Suna Zhou ◽

Xuequan Wang ◽

Jiapei Ding ◽

Haihua Yang ◽

Youyou Xie

Keyword(s):

Cervical Cancer ◽

Cancer Patients ◽

Poor Prognosis ◽

Cox Regression ◽

Functional Enrichment ◽

Functional Study ◽

Migration And Invasion ◽

Dual Function ◽

Mesenchymal Transition ◽

Incidence And Mortality

Cervical cancer has the second-highest incidence and mortality of female malignancy. The major causes of mortality in patients with cervical cancer are invasion and metastasis. The epithelial–mesenchymal transition (EMT) process plays a major role in the acquisition of metastatic potential and motility. Autophagy-related genes (ARGs) are implicated in the EMT process, and autophagy exerts a dual function in EMT management at different phases of tumor progression. However, the role of specific ARGs during the EMT process has not yet been reported in cervical cancer. Based on the data from the Cancer Genome Atlas (TCGA) cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) sequencing database, we performed the prognosis analysis for those ARGs obtained from the Human Autophagy database. ATG5 was identified as the only important harmful marker influencing survival of cervical cancer patients by univariate Cox regression (HR 1.7; 95% CI: 1.0–2.8, p = 0.047), and the 5-years survival rate for the high- and low-ATG5 expression groups was 0.486 (0.375–0.631) and 0.782 (0.708–0.863), respectively. TCGA CESC methylation data showed that eight methylation sites of ATG5 could also be significantly associated with the overall survival (OS) of cervical cancer patients. Single-sample gene-set enrichment and gene functional enrichment results showed that ATG5 was correlated with some cancer-related pathways, such as phagocytosis-related genes, endocytosis-related genes, immune-related genes, EMT score, and some EMT signature-related genes. Next, cell migration and invasion assay and Western blot were applied to detect the function of ATG5 in EMT of cervical cancer. In cervical cancer cells, ATG5 knockdown resulted in attenuation of migration and invasion. The functional study showed that knockdown of ATG5 could reverse EMT process by P-ERK, P-NFκBp65, P-mTOR pathways, and so on. In conclusion, the present study implies that ATG5 was a major contributor to EMT regulation and poor prognosis in cervical cancer.

Download Full-text

Abstract 4215: SPAG5 upregulation predicts poor prognosis of cervical cancer patients and alters the sensitivity of Taxol treatment via mTOR signaling pathway

10.1158/1538-7445.am2014-4215 ◽

2014 ◽

Cited By ~ 1

Author(s):

Lin-Jing Yuan ◽

Lan Zhang ◽

Yun Zhou ◽

Min Zheng

Keyword(s):

Cervical Cancer ◽

Cancer Patients ◽

Signaling Pathway ◽

Poor Prognosis ◽

Mtor Signaling ◽

Mtor Signaling Pathway

Download Full-text

Up-regulated microRNA-155 expression is associated with poor prognosis in cervical cancer patients

Biomedicine & Pharmacotherapy ◽

10.1016/j.biopha.2016.06.006 ◽

2016 ◽

Vol 83 ◽

pp. 64-69 ◽

Cited By ~ 25

Author(s):

Hui Fang ◽

Dong Shuang ◽

Zhong Yi ◽

Hu Sheng ◽

Yang Liu

Keyword(s):

Cervical Cancer ◽

Cancer Patients ◽

Poor Prognosis

Download Full-text

335 poster Optimisation of radiotherapy and multimodality therapy for cervical cancer patients with poor prognosis

Radiotherapy and Oncology ◽

10.1016/s0167-8140(03)80352-3 ◽

2003 ◽

Vol 68 ◽

pp. S116

Keyword(s):

Cervical Cancer ◽

Cancer Patients ◽

Poor Prognosis ◽

Multimodality Therapy ◽

Patients With Poor Prognosis

Download Full-text

B7-H4 overexpression correlates with a poor prognosis for cervical cancer patients

Molecular and Clinical Oncology ◽

10.3892/mco.2013.225 ◽

2013 ◽

Vol 2 (2) ◽

pp. 219-225 ◽

Cited By ~ 14

Author(s):

WENTING LIU ◽

KIYOSUMI SHIBATA ◽

YOSHIHIRO KOYA ◽

HIROAKI KAJIYAMA ◽

TAKESHI SENGA ◽

...

Keyword(s):

Cervical Cancer ◽

Cancer Patients ◽

Poor Prognosis

Download Full-text

FSCN1 Promotes Radiation Resistance in Patients With PIK3CA Gene Alteration

Frontiers in Oncology ◽

10.3389/fonc.2021.653005 ◽

2021 ◽

Vol 11 ◽

Author(s):

Sisi Li ◽

Xiao-ting Huang ◽

Meng-yao Wang ◽

Dong-ping Chen ◽

Ming-yi Li ◽

...

Keyword(s):

Cervical Cancer ◽

Head And Neck Cancer ◽

Head And Neck ◽

Cancer Cells ◽

Cancer Patients ◽

Clinical Efficacy ◽

Neck Cancer ◽

Radiation Resistance ◽

Poor Prognosis ◽

Pik3ca Mutation

Radiotherapy is one of the standard treatments for cervical cancer and head and neck cancer. However, the clinical efficacy of this treatment is limited by radioresistance. The discovery of effective prognostic biomarkers and the identification of new therapeutic targets have helped to overcome the problem of radioresistance. In this study, we show that in the context of PIK3CA mutation or amplification, high expression of fascin actin-bundling protein 1 (FSCN1) (using the median as the cut-off value) is associated with poor prognosis and radiotherapy response in cancer patients. Silencing FSCN1 enhances radiosensitivity and promotes apoptosis in cancer cells with PIK3CA alterations, and this process may be associated with the downregulation of YWHAZ. These results reveal that FSCN1 may be a key regulator of radioresistance and could be a potential target for improving radiotherapy efficacy in cervical cancer and head and neck cancer patients with PIK3CA alterations.

Download Full-text